Composição e processo de produção de sistema de liberação controlada contendo agente para regeneração óssea guiada e kit, método de PCR multiplex one-tube e oligonucleotídeos com e sem marcação fluorescente: uso individual e/ou combinado para diagnóstico diferencial de 22 síndromes respiratórias humanas

Abstract

Part I: Currently, tissue engineering has been undergoing great evolution with the use of nanobiotechnology. Increasingly, alternatives are being sought for repairing and replacing body tissues that preserve function and characteristics, in addition to greater biocompatibility. In this context, nanostructured scaffolds have proven to be a good alternative for bone tissue repair due to their ability to support cells, pores that develop an environment conducive to their communication and proliferation, ability to be bioabsorbed, in addition to being able to be associated with drugs, that can lead to increased differentiation of stem cells in the region. Chapter 1 presents a contextualization of the theme, justifying the importance of the objectives of this first part, which is the validation of nanostructured scaffolds composed of PLA/PEG (poly(lactic acid)/poly(ethylene glycol)) associated with Simvastatin. Chapter 2 brings the patent already deposited at the National Institute of Intellectual Property (INPI), referring to the process of production of PLA/PEG scaffolds with or without simvastatin, which showed good preliminary results with prospects for application in bone regeneration. Part II: In January 2020, the World Health Organization (WHO) declared a pandemic state due to the large number of COVID-19 cases around the world and the rapid spread of the SARS-CoV-2 virus. of severe acute respiratory syndrome) causing the death of thousands of people. Given this statistic, it is essential to diagnose the largest number of cases quickly and effectively to direct the treatment and control of the disease. However, differentiating other acute respiratory infections (ARIs) in the current SARS-CoV-2 pandemic is essential to guide the choice of the most appropriate individual therapy, collective measures to prevent dissemination, also prevent the dissemination of secondary nosocomial infections, avoid bacterial resistance and reduce the burden on health units. Chapter 3 contextualizes the situation of the pandemic in which we live and other flu syndromes that can be confused with COVID-19, as well as its epidemiological data in order to justify the objective of this part, which consists of the development of a new differential diagnostic platform based on in multiplex PCR. Chapter 4 presents the patent that will still be deposited, claiming the use of oligonucleotides designed for this platform and the amplification method of all targets in a single tube with simultaneous detection of these targets.